Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Cluzeau

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Leukemia|April 16, 2011
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemiasR Itzykson, O Kosmider, T Cluzeau, et al.
Leukemia|October 31, 2015
Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromesD A Sallman, R Komrokji, C Vaupel, et al.
Leukemia|September 22, 2023
Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trialA S Kubasch, P Peterlin, T Cluzeau, et al.
Bone Marrow Transplantation|February 9, 2016
Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHIT Cluzeau, J Lambert, N Raus, et al.
Leukemia & Lymphoma|February 18, 2021
Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemiaS Fodil, E Raffoux, P Y Dumas, et al.
The British Journal of Dermatology|October 11, 2021
Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patientsS Georgin-Lavialle, B Terrier, A F Guedon, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Leukemia|April 16, 2011
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemiasR Itzykson, O Kosmider, T Cluzeau, et al.
Leukemia|October 31, 2015
Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromesD A Sallman, R Komrokji, C Vaupel, et al.
Leukemia|September 22, 2023
Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trialA S Kubasch, P Peterlin, T Cluzeau, et al.
Bone Marrow Transplantation|February 9, 2016
Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHIT Cluzeau, J Lambert, N Raus, et al.
Leukemia & Lymphoma|February 18, 2021
Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemiaS Fodil, E Raffoux, P Y Dumas, et al.
The British Journal of Dermatology|October 11, 2021
Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patientsS Georgin-Lavialle, B Terrier, A F Guedon, et al.
Pageof 2